Module 2.4 — Nonclinical Overview
| Field | Value |
|---|---|
| Document ID | M24 |
| Version | 3.0 (full, aligned to M4) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH M4S(R2) · M3(R2) · S1–S8 |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]No nonclinical wet-lab data are generated; guideline-structured, scientifically coherent narrative with illustrative values. Detailed study reports in M4 (4.2.1–4.2.3); tabulated summaries in M2.6.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Nonclinical | Initial |
| 2.0 | 2026-06-29 | Nonclinical | Full — exposure margins, translational assessment |
| 3.0 | 2026-06-30 | Nonclinical | Aligned to detailed M4 — explicit potency/PK values, specific NOAEL margins, C-cell human-relevance & issue management |
1. Nonclinical Testing Strategy
Designed per ICH M3(R2) (study timing relative to clinical phases) and the ICH S-series, using the rat (rodent) and cynomolgus monkey (non-rodent) to characterise dual pharmacology, ADME, and toxicology adequate for Phase 1–3 and registration. Peptide-specific considerations (immunogenicity, IV local tolerance, the SNAC permeation enhancer) were included.
2. Pharmacology (M4-2.1)
2.1 Primary pharmacodynamics
- In-vitro potency/selectivity: full agonism at human GLP-1R (cAMP EC₅₀ ≈ 14 pM) and APJ (EC₅₀ ≈ 48 pM, G-protein-biased), with no activity at the GIP or glucagon receptors — confirming a clean dual-agonist profile.
- In-vivo efficacy (db/db, DIO): dose-dependent HbA1c (high dose −1.8% vs −1.1% for the GLP-1R-only comparator) and body-weight (−18% vs −12%) effects at matched exposure, with a +58% increase in clamp glucose-infusion rate (insulin sensitivity) and −34% NT-proBNP — the APJ-attributable cardiometabolic benefit, with echocardiographic/endothelial readouts confirming in-vivo APJ engagement.
2.2 Secondary & safety pharmacology (S7A/S7B)
No off-target hits (~80-target screen); hERG IC₅₀ >30 µM (>1,000× margin); no QTc prolongation; no adverse CNS/respiratory effects; only a transient, monitorable, mechanism-related heart-rate increase (+10–15%).
3. Pharmacokinetics (M4-2.2; S3A)
Low clearance and a long half-life driven by >99% albumin binding (C18-diacid acylation) plus DPP-4 resistance (Aib substitutions) — supporting once-weekly IV dosing; single-digit-% oral bioavailability with the SNAC enhancer (basis for the 8 mg oral vs 4 mg IV dose). Metabolism is proteolytic (non-CYP) with low drug-interaction potential; ADA were low-titre and non-neutralising.
4. Toxicology (M4-2.3; S-series)
- Repeat-dose (26-wk rat / 39-wk monkey, GLP): adverse findings limited to reversible exaggerated-pharmacology (reduced food intake/weight gain) and reversible injection-site reactions; no adverse target-organ toxicity; NOAEL = high dose in both species.
- Genotoxicity (S2): complete battery negative.
- Carcinogenicity (S1): a dose-related thyroid C-cell hyperplasia/adenoma in the 2-year rat — the expected rodent GLP-1 class effect; rasH2 mouse negative. A mechanistic human-relevance analysis (high rodent C-cell GLP-1R density vs very low human; no class MTC signal) classifies this as largely rodent-specific (managed as issue QA-003 ISS-012), conservatively carried as a labeled class risk (MTC/MEN-2 contraindication; RMP).
- Reproductive/developmental (S5(R3)): effects limited to maternal toxicity (reduced food intake/weight) with associated foetal-weight reductions; no unique teratogenicity.
- Acceptable local tolerance and immunotoxicity; impurities qualified.
5. Integrated Exposure-Margin Assessment
| Study | NOAEL | Margin to clinical AUC |
|---|---|---|
| Repeat-dose rat (26 wk) | high dose (3.0 mg/kg/wk) | ≈25× |
| Repeat-dose monkey (39 wk) | high dose | ≈20× |
| Reproductive (rat/rabbit) | maternal-toxicity-limited | adequate developmental margin |
| Margins support the proposed clinical doses (IV 4 mg QW; Oral 8 mg QD). |
6. Translational Assessment & Integrated Conclusions
The nonclinical findings translate to monitorable clinical risks carried as adverse events of special interest (gastrointestinal tolerability, thyroid C-cell/MTC, pancreatitis, cardiovascular/heart-rate) (PROT-301 §10; RMP). The package establishes the dual GLP-1/APJ mechanism, a class-consistent and manageable safety profile, and adequate exposure margins — supporting clinical development and registration, with the single notable finding (rodent C-cell carcinogenicity) investigated and managed as a labeled, low-human-relevance class risk.